|PUBLICATIONS (Ranked by impact factor of the journal)|
Association between CD8+ T-Cell Infiltration and Breast Cancer Survival in 12 439 Patients
T-cell infiltration in estrogen receptor-negative breast tumors has been associated with longer survival. To investigate this association and the potential of tumor T-cell infiltration as a prognostic and predictive marker, researchers conducted the largest study of T cells in breast cancer to date. [Ann Oncol]
Targeting WNT1-Inducible Signaling Pathway Protein 2 Alters Human Breast Cancer Cell Susceptibility to Specific Lysis through Regulation of KLF-4 and miR-7 Expression
Investigators found that silencing WNT1-inducible signaling pathway protein 2 signaling in human breast adenocarcinoma MCF7 cells impairs cytotoxic T-lymphocyte-mediated cell killing by a mechanism involving stem cell marker Kruppel-like factor-4 induction and microRNA-7 (miR-7) downregulation. [Oncogene]
A Role for CCL28-CCR3 in T-Cell Homing to the Human Upper Airway Mucosa
Analysis of the cognate chemokine receptors revealed that close to 50% of the CD4+ T cells in the human nasal mucosa expressed the CCL28 receptor CCR3, whereas CCR3 was hardly detectable on T cells in the small intestine and skin. In the circulation, CCR3+ T cells comprised a small subset that did not express homing receptors to the intestine or skin. [Mucosal Immunol]
Association between Group 2 Innate Lymphoid Cells Enrichment, Nasal Polyps and Allergy in Chronic Rhinosinusitis
Researchers characterized group 2 innate lymphoid cell (ILC2) compartment in chronic rhinosinusitis (CRS) by investigating the correlations between ILC2s, Th2 cells and Th2 cytokines expression in CRS patients. [Allergy]
A High Frequency of Myeloid-Derived Stem Cells (MDSCs) in Sepsis Patients, with the Granulocytic Subtype Dominating in Gram-Positive Cases
Investigators analyzed potential MDSCs in sepsis patients with different causative microorganisms, using total peripheral blood compared with density gradient-centrifuged blood. [J Leukoc Biol]
Upregulation of Store-Operated Ca2+ Entry in the Naïve CD4+ T Cells with Aberrant Cytokine Releasing in Active Rheumatoid Arthritis
Researchers measured Ca2+ influx and Ca2+ release-activated Ca2+ currents in naïve and memory CD4+ T cells. These cells were further characterized by flow cytometric analysis of interleukin (IL)-4, IL-17, interferon-γ and tumor necrosis factor-α. [Immunol Cell Biol]
Clinical Heterogeneity of Immunodysregulation, Polyendocrinopathy, Enteropathy, X-linked: Pulmonary Involvement as a Non-Classical Disease Manifestation
Immunodysregulation, Polyendocrinopathy, Enteropathy, X-linked is a rare X-linked recessive life-threatening disorder characterized by autoimmunity and early death. Clinical data and laboratory findings including autoantibodies, immunoglobulin levels as well as number of T, B and NK cells were evaluated. FOXP3 expression and T reg activity were analyzed. [J Clin Immunol]
Pre-TCRα Supports CD3-Dependent Reactivation and Expansion of TCRα-Deficient Primary Human T-Cells
Researchers showed that pre-T-cell receptor (TCR) α, a TCRα surrogate that pairs with TCRβ chains to signal proper TCRβ folding during T-cell development, can be expressed in TCRα knockout mature T-cells to support CD3 expression at the cell surface. [Mol Ther Methods Clin Dev]
Heading to ISSCR 2014 in Vancouver?
Come Visit Connexon Creative at Booth #507 and Enter to Win $100 Amazon Gift Card!
|Subscribe to our sister publications: Immunology of Infectious Disease News
and Immune Regulation News!|
MorphoSys and Merck Serono Enter Strategic Immuno-Oncology Collaboration
MorphoSys AG and Merck announced that they have signed an agreement to discover and develop therapeutic antibodies against undisclosed immune checkpoints. Under the terms of the agreement, MorphoSys and Merck Serono will join forces to develop therapies that modulate the immune system’s natural ability to fight tumors. [MorphoSys AG]
Hyperion Therapeutics Completes Acquisition of Andromeda Biotech, Ltd.
Hyperion Therapeutics, Inc. announced that it has completed its acquisition of Andromeda Biotech Ltd. The acquisition broadens Hyperion’s pipeline to include DiaPep277®, a potentially first-in-class immunotherapy for new onset Type 1 diabetes. [Hyperion Therapeutics, Inc.]
Virginia G. Piper Cancer Center Vaccine Study Hopes to Improve Pancreatic Cancer Treatment
Medical investigators at the Virginia G. Piper Cancer Center at Scottsdale Healthcare are studying a new cancer immunotherapy to see if it can successfully help patients with advanced pancreatic cancer. [Translational Genomics Research Institute]
Grant Supports Innovative Immunotherapy Research at Baylor
Baylor College of Medicine, Texas Children’s Cancer Center and Center for Cell and Gene Therapy researcher Dr. Stephen Gottschalk has received a $250,000 Innovation Award from Alex’s Lemonade Stand Foundation to support his work to find innovative new treatments for childhood cancer. [Baylor College of Medicine]
First-of-Its-Kind Pediatric Research and Funding Collaboration to Speed Development of Medications for Autoimmune Diseases
Seattle Children’s Research Institute and Kineta, Inc. launched the Alliance for Children’s Therapeutics, a first-of-its-kind pediatric research and funding collaboration designed to speed development of new medications for children and teens with lupus nephritis and other autoimmune diseases like multiple sclerosis, Type 1 diabetes and rheumatoid arthritis. [Seattle Children’s Research Institute]
Have we missed an important article or publication in Human Immunology News?
Click here to submit!
Comments or Suggestions? Submit your feedback here.